Bora CDMO Bora CDMO

X

Find Radio Compass News for Bivalirudin

PharmaCompass
Related ProductsRelated Products
API SUPPLIERS
API Suppliers

API Suppliers

US DMFs Filed

US DMFs Filed

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

0

Other Certificates

Other Certificates

Other Suppliers

Other Suppliers

API REF. PRICE (USD / KG)
INTERMEDIATES

0

DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

Europe

Europe

Canada

Canada

Australia

Australia

South Africa

South Africa

0

Uploaded Dossiers

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

EXCIPIENTS
PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

SERVICES

0

left grey arrow
right gray arrow
  • SOLUTION;INTRAVENOUS - 250MG/50ML (5MG/ML)
  • SOLUTION;INTRAVENOUS - 500MG/100ML (5MG/ML)
  • INJECTABLE;INTRAVENOUS - 250MG/VIAL

https://www.prnewswire.com/news-releases/endo-launches-bivalirudin-injection-in-ready-to-use-vials-301880137.html

PR NEWSWIRE
18 Jul 2023

http://www.pharmabiz.com/NewsDetails.aspx?aid=126687&sid=2

PHARMABIZ
08 Jun 2020

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210031

FDA
25 Oct 2019

https://www.forbes.com/sites/annemarieknott/2019/03/11/the-medicines-company-innovating-innovation/#726b9aa35ae1

Anne Marie Knott FORBES
11 Mar 2019

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/nod-for-aurobindo-pharma-to-make-market-bivalirudin-injection/articleshow/65196682.cms

ECONOMIC TIMES
30 Jul 2018

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205962

FDA
28 Jul 2018

https://www.drugdeliverybusiness.com/mylan-launches-generic-drug-delivery-patch-for-dementia-patients/

Sarah Faulkner DRUG DEL BUSINESS
09 Jul 2018

https://www.biospectrumasia.com/news/34/11108/mylan-announces-us-launch-of-bivalirudin-for-injection.html

BIOSPECTRUM
18 Jun 2018

https://www.prnewswire.com/news-releases/mylan-launches-generic-angiomax-injection-300667911.html

PR NEWSWIRE
18 Jun 2018

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202471

FDA
05 Jun 2018

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204876

FDA
07 Jul 2017

http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202471

FDA
10 Feb 2017

http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=091468

FDA
02 Feb 2017

https://www.statnews.com/pharmalot/2016/05/05/appeals-court-patent-drug-makers/

Ed Silverman STAT
05 May 2016

http://cphi-online.com/eagle-pharmaceuticals-receives-complete-response-news039629.html

CPHI ONLINE
21 Mar 2016

http://www.reuters.com/article/us-eagle-pharms-fda-idUSKCN0WK18V

Rosmi Shaji REUTERS
19 Mar 2016

http://www.fdanews.com/articles/172061-federal-circuit-revokes-the-medicines-cos-angiomax-patents

FDA NEWS
13 Jul 2015

http://manufacturing.pharmaceutical-business-review.com/news/the-medicines-company-authorizes-generic-launch-of-angiomax-100715-4620497?utm_term=Pharma&utm_source=PBR&utm_medium=twitter

PBR
10 Jul 2015

http://www.businesswire.com/news/home/20150702005697/en/Federal-Circuit-Rules-Medicines-Company-Angiomax%C2%AE-bivalirudin#.VZZCiRuqqkp

BUSINESS WIRE
03 Jul 2015

http://www.fiercebiotech.com/story/after-phiii-odyssey-fda-finally-gives-medicines-co-thumbs-cangrelor/2015-04-13

John Carroll FIERCE BIOTECH
14 Apr 2015

http://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/sun-pharma-settles-angiomax-litigation-with-the-medicines-company/articleshow/46773726.cms

Press Trust Of India THE ECONOMIC TIMES
03 Apr 2015
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY